Brief: Sanofi And Regeneron’S Dupixent Approved In The U.S. For Allergic Fungal Rhinosinusitis
24/02/2026 14:33
Feb 24 (Reuters) - Sanofi SA SASY.PA: SANOFI AND REGENERON’S DUPIXENT APPROVED IN THE US AS THE FIRST AND ONLY MEDICINE FOR ALLERGIC FUNGAL RHINOSINUSITIS PHASE 3 STUDY SHOWS DUPIXENT REDUCES NASAL SIGNS AND SYMPTOMS DUPIXENT IS NOW APPROVED IN US TO TREAT NINE DISTINCT DISEASES DRIVEN IN PART BY TYPE 2 INFLAMMATION APPROVAL EXPANDS OUR APPROVED INDICATIONS IN SINO-NASAL DISEASES TO NOW INCLUDE AFRS, ALONGSIDE CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Source text: ID:nGNX7lkHgB Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes